AMRN
BEARISH
$15.34
Live
Amarin Corporation plc · NASDAQ
Target $12.0
(-21.8%)
$7.6
52W Range
$20.9
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$319.13M
P/E
N/A
ROE
-8.2%
Profit margin
-18.2%
Debt/Equity
0.02
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
AMRN's Piotroski F-Score of 2/9 indicates severe financial distress, with weak profitability, declining revenue, and negative earnings trends. The absence of an Altman Z-Score raises concern about potential bankruptcy risk, especially given the company's negative ROE, ROA, and persistent losses despite a strong gross margin. While the company exhibits a low debt-to-equity ratio and high liquidity, these strengths are overshadowed by a 21% YoY revenue decline and a 94.7% Q/Q EPS drop. Analysts have issued a 'underperform' rating with a target price below current levels, reflecting skepticism about near-term sustainability. The stock's recent 87% 1-year gain is likely driven by speculative momentum rather than fundamentals.
Key Strengths
High gross margin of 56.57% suggests strong pricing power or cost control in production
Extremely low debt-to-equity ratio of 0.02 indicates minimal financial leverage and low default risk
Strong liquidity with current ratio of 3.34 and quick ratio of 2.21, providing buffer against short-term obligations
Recent positive earnings surprises in prior quarters (e.g., +242.6% in 2025-07-30) indicate potential for earnings recovery
Significant 1-year price appreciation (+87.1%) suggests strong market sentiment and potential for short-term momentum
Key Risks
Piotroski F-Score of 2/9 signals severe financial weakness, with multiple red flags including negative ROE, ROA, and declining profitability
21% year-over-year revenue decline and negative earnings growth indicate deteriorating business fundamentals
No analyst consensus on forward earnings, with target price of $12.00 below current price, signaling bearish outlook
Absence of a Graham Number and Intrinsic Value suggests no reliable valuation anchor, increasing speculative risk
Insider trading activity is neutral with zero buy/sell transactions in the last 6 months, indicating lack of confidence or interest
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
27
Weak
40
30
45
20
0
AI Verdict
weak
Key drivers: Low Piotroski F-Score (2/9), Negative profitability and revenue decline, Lack of analyst consensus and downward target price, High volatility and speculative price performance
Confidence
85%
Value
40/100
Ref P/E, PEG, Graham Number
Positives
- Price/Book of 0.70 suggests trading below book value
- Price/Sales of 1.49 is moderate for a biotech with high growth expectations
Watchpoints
- No Graham Number or intrinsic value estimate available
- Forward P/E of 13.11 is misleading due to negative historical earnings
- Stock trades at a premium to book value despite negative ROE and profitability
Future
30/100
Ref Growth rates
Positives
- Recent positive earnings surprises in prior quarters (e.g., +242.6%) suggest potential for recovery
- High Q/Q EPS growth of +102.5% indicates possible turnaround momentum
Watchpoints
- 21% YoY revenue decline signals ongoing business contraction
- Most recent Q/Q EPS growth is -94.7%, indicating worsening performance
- No forward earnings guidance or reliable growth projections
Past
45/100
Ref Historical trends
Positives
- Historical earnings have shown significant volatility with large positive surprises
- Some quarters have exceeded estimates by over 200% (e.g., 2025-07-30)
Watchpoints
- Persistent losses over multiple quarters with negative ROE and ROA
- Negative earnings growth and declining revenue trend
- Multiple quarters with large negative surprises (e.g., -1500% in 2022-05-04)
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Extremely low debt-to-equity ratio (0.02) and strong liquidity (current ratio 3.34)
- No indication of immediate liquidity crisis
Watchpoints
- Piotroski F-Score of 2/9 is extremely low, indicating severe financial distress
- Negative ROE (-8.21%), ROA (-1.29%), and profit margin (-18.16%)
- No Altman Z-Score available, but the financial profile suggests distress risk
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100, indicating no dividend policy
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$15.34
Analyst Target
$12.0
Upside/Downside
-21.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AMRN and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AMRN
Amarin Corporation plc
Primary
|
-88.3% | -51.5% | +87.1% | +2.2% | +1.5% | +9.1% |
|
RXST
RxSight, Inc.
Peer
|
-52.4% | -56.2% | -47.3% | -7.7% | +3.5% | +11.4% |
|
CV
CapsoVision, Inc.
Peer
|
+79.0% | +79.0% | +79.0% | +33.0% | +22.8% | -14.1% |
|
ORGO
Organogenesis Holdings Inc.
Peer
|
-87.9% | +26.2% | -39.8% | -36.1% | +0.8% | +8.8% |
|
ACIU
AC Immune SA
Peer
|
-62.7% | +31.1% | +31.1% | +24.1% | -0.5% | +8.1% |
AMR
Amarin Corporation plc
Primary
5Y
-88.3%
3Y
-51.5%
1Y
+87.1%
6M
+2.2%
1M
+1.5%
1W
+9.1%
RXS
RxSight, Inc.
Peer
5Y
-52.4%
3Y
-56.2%
1Y
-47.3%
6M
-7.7%
1M
+3.5%
1W
+11.4%
CV
CapsoVision, Inc.
Peer
5Y
+79.0%
3Y
+79.0%
1Y
+79.0%
6M
+33.0%
1M
+22.8%
1W
-14.1%
ORG
Organogenesis Holdings Inc.
Peer
5Y
-87.9%
3Y
+26.2%
1Y
-39.8%
6M
-36.1%
1M
+0.8%
1W
+8.8%
ACI
AC Immune SA
Peer
5Y
-62.7%
3Y
+31.1%
1Y
+31.1%
6M
+24.1%
1M
-0.5%
1W
+8.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
13.11
PEG Ratio
N/A
P/B Ratio
0.7
P/S Ratio
1.49
EV/Revenue
28.5
EV/EBITDA
-557.89
Market Cap
$319.13M
Profitability
Profit margins and return metrics
Profit Margin
-18.16%
Operating Margin
-4.59%
Gross Margin
56.57%
ROE
-8.21%
ROA
-1.29%
Growth
Revenue and earnings growth rates
Revenue Growth
-21.0%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.02
Low debt
Current Ratio
3.34
Strong
Quick Ratio
2.21
Excellent
Cash/Share
$0.73
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-02-25
$0.01
-85.7% surprise
2025-10-29
$0.19
2025-07-30
$0.87
+242.6% surprise
Healthcare Sector Comparison
Comparing AMRN against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-8.21%
This Stock
vs
-88.14%
Sector Avg
-90.7%
(Below Avg)
Profit Margin
-18.16%
This Stock
vs
-16.28%
Sector Avg
+11.5%
(Superior)
Debt to Equity
0.02
This Stock
vs
2.66
Sector Avg
-99.3%
(Less Debt)
Revenue Growth
-21.0%
This Stock
vs
124.04%
Sector Avg
-116.9%
(Slower)
Current Ratio
3.34
This Stock
vs
4.47
Sector Avg
-25.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AMRN
Amarin Corporation plc
|
BEARISH | $319.13M | - | -8.2% | -18.2% | $15.34 | |
|
RXST
RxSight, Inc.
|
BEARISH | $314.04M | - | -14.0% | -29.0% | $7.61 | Compare |
|
CV
CapsoVision, Inc.
|
BEARISH | $312.24M | - | -184.9% | -186.8% | $6.26 | Compare |
|
ORGO
Organogenesis Holdings Inc.
|
NEUTRAL | $334.47M | 16.25 | 9.0% | 6.6% | $2.6 | Compare |
|
ACIU
AC Immune SA
|
BEARISH | $303.31M | - | -74.6% | -% | $3.02 | Compare |
AMRN
Amarin Corporation plc
BEARISH
Mkt Cap
$319M
P/E
-
ROE
-8.2%
Price
$15.34
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-30 | BERG AARON D. | Chief Executive Officer | Stock Award | 4,179 | - |
| 2026-01-30 | FISHMAN PETER L | Chief Financial Officer | Stock Award | 2,396 | - |
| 2026-01-30 | KEENAN DAVID PAUL | Chief Operating Officer | Stock Award | 4,179 | - |
| 2026-01-30 | KETCHUM STEVEN B | Officer | Stock Award | 4,179 | - |
| 2026-01-02 | PROVOOST JONATHAN | Officer | Stock Award | 3,688 | - |
| 2026-01-02 | FISHMAN PETER L | Chief Financial Officer | Stock Award | 2,447 | - |
| 2026-01-02 | KEENAN DAVID PAUL | Chief Operating Officer | Stock Award | 3,688 | - |
| 2026-01-02 | KETCHUM STEVEN B | Officer | Stock Award | 3,688 | - |
BERG AARON D.
Chief Executive Officer
2026-01-30
4,179 shares
FISHMAN PETER L
Chief Financial Officer
2026-01-30
2,396 shares
KEENAN DAVID PAUL
Chief Operating Officer
2026-01-30
4,179 shares
KETCHUM STEVEN B
Officer
2026-01-30
4,179 shares
PROVOOST JONATHAN
Officer
2026-01-02
3,688 shares
FISHMAN PETER L
Chief Financial Officer
2026-01-02
2,447 shares
KEENAN DAVID PAUL
Chief Operating Officer
2026-01-02
3,688 shares
KETCHUM STEVEN B
Officer
2026-01-02
3,688 shares
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning AMRN from our newsroom.
Newest → oldest
No matching news yet.